AbCellera Biologics
ABCL
141 hedge funds and large institutions have $525M invested in AbCellera Biologics in 2025 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 43 increasing their positions, 35 reducing their positions, and 22 closing their positions.
84% more call options, than puts
Call options by funds: $9.54M | Put options by funds: $5.18M
59% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 22
42% more capital invested
Capital invested by funds: $371M → $525M (+$154M)
23% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 35
10% more funds holding
Funds holding: 128 → 141 (+13)
1.25% less ownership
Funds ownership: 36.07% → 34.81% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$9.67M |
| 2 |
Morgan Stanley
New York
|
+$7.91M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$5.41M |
| 4 |
Two Sigma Investments
New York
|
+$4.69M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$29.1M |
| 2 |
O
OrbiMed
New York
|
-$11.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.29M |
| 4 |
Millennium Management
New York
|
-$4.27M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.23M |
ABCL Hedge Fund Activity: Q3 2025 in Review
141 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q3 2025, worth a combined $525M — up 42% from $371M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ABCL positions and 22 closed out — a net gain of 13 holders — while 43 added to existing stakes and 35 trimmed.
The largest buyer was Bank of America, adding an estimated $9.67M. The largest seller was UBS AM, exiting entirely with an estimated $29.1M sold.
- 141 institutional investors held AbCellera Biologics (ABCL) as of Q3 2025, up from 128 in Q2 2025.
- Funds reported $525M of AbCellera Biologics stock for Q3 2025, up 42% quarter-over-quarter.
- 35 funds opened new AbCellera Biologics positions in Q3 2025 and 22 closed out, a net change of +13 holders.
- The largest AbCellera Biologics buyer in Q3 2025 was Bank of America, an estimated $9.67M added.
- The largest AbCellera Biologics seller in Q3 2025 was UBS AM, an estimated $29.1M sold.
Based on aggregated 13F filings for Q3 2025.